Volume 9, Number 6—June 2003
Dispatch
Fluoroquinolone Use and Clostridium difficile–Associated Diarrhea
Margaret E. McCusker*, Anthony D. Harris†, Eli N. Perencevich†, and Mary-Claire Roghmann*†
Table 1
Characteristics of CDAD cases and matched controls, Veterans Affairs Maryland Health Care System, January 1, 2001–June 30, 2001
| Characteristic | Cases (n=30)a | Controls (n=60)a | p value |
|---|---|---|---|
| Age, median y |
72 (66–79)b |
67 (56–76)b |
0.30 |
| Diagnosis causing admission |
|||
| Infectious |
11 (37) |
11 (18) |
0.07 |
| Cardiovascular |
5 (17) |
14 (23) |
0.59 |
| Neurologic/psychiatric |
3 (10) |
15 (25) |
0.16 |
| Gastroenterologic |
2 (7) |
4 (7) |
1.00 |
| Respiratory |
1 (3) |
5 (8) |
0.66 |
| Other |
8 (27) |
11 (18) |
0.42 |
| Antibiotics within 6 weeks |
30 (100) |
38 (63) |
<0.01 |
| Cephalosporins |
7 (23) |
20 (33) |
0.30 |
| Clindamycin |
9 (30) |
7 (12) |
0.03 |
| Fluoroquinolones |
22 (73) |
15 (25) |
<0.01 |
| Piperacillin/tazobactam |
12 (40) |
18 (30) |
0.30 |
| All other antibiotics |
17 (57) |
27 (45) |
0.30 |
| Days at risk for CDADc, median | 21(10–30)b | 13(7–25)a | 0.18 |
aUnless otherwise indicated, values in parentheses show percentages.
bValue in parentheses shows interquartile range.
cCDAD, Clostridium difficile–associated diarrhea.
Page created: December 21, 2010
Page updated: December 21, 2010
Page reviewed: December 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.